US equities
|
NVDA
$192.45
▲+5.97%
MU
$719.55
▲+9.62%
AMD
$455.14
▲+12.55%
SNDK
$907.72
▲+12.56%
SPCX
$130.56
▲+5.61%
TSLA
$354.68
▲+3.20%
AAPL
$343.26
▼-0.26%
GOOGL
$287.27
▲+1.67%
NVDA
$192.45
▲+5.97%
MU
$719.55
▲+9.62%
AMD
$455.14
▲+12.55%
SNDK
$907.72
▲+12.56%
SPCX
$130.56
▲+5.61%
TSLA
$354.68
▲+3.20%
AAPL
$343.26
▼-0.26%
GOOGL
$287.27
▲+1.67%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Corvus Pharmaceuticals, Inc. - Common Stock
(NQ:
CRVS
)
9.860
+0.130 (+1.34%)
Delayed Quote
Updated: 9:45 AM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Corvus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
Next >
Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
January 23, 2024
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
December 09, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
November 02, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
November 01, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
October 31, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
September 06, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
August 01, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
July 06, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
June 29, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
May 17, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
May 08, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
April 20, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
April 17, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
April 03, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
March 21, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
March 14, 2023
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad...
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
February 21, 2023
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
December 12, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
December 05, 2022
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
November 14, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
November 03, 2022
Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 27, 2022
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
October 25, 2022
From
Corvus Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
September 28, 2021
Via
FinancialNewsMedia
< Previous
1
2
Next >
